ArticleInternational journal of molecular sciences2025
RETRACTED: Cejuela et al. Metformin and Breast Cancer: Where Are We Now?
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Article
- Metformin triggers apoptosis via endoplasmic reticulum stress in HER2-positive breast cancer cell lines.Experimental and therapeutic medicine · 2026Article
- Emerging uncertainty on the anti-aging potential of metformin.Ageing research reviews · 2025Review
- Molecular Mechanism of Metformin Regulating the Regeneration of PlanarianInternational journal of molecular sciences · 2025Article
- Metformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers.Scientific reports · 2025Article
- Multi-omics profile of exceptional long-term survivors of AJCC stage III triple-negative breast cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Obesity-cancer axis crosstalk: Molecular insights and therapeutic approaches.Acta pharmaceutica Sinica. B · 2025Review
- Association between dyslipidemia and breast cancer risk: a retrospective case-control study stratified by menopausal status.American journal of translational research · 2025Article
- Metformin enhances alpelisib sensitivity in HER2+ breast cancer by suppressing cancer stemness and oncogenic signaling.Frontiers in oncology · 2025Article
Corrections and comments
- Retraction of
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The journal retracts the article titled "Metformin and Breast Cancer: Where Are We Now [...].
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.